Nitrosamine impurities in medications: Recalls
On this page
- What you should do
- Acyclovir recalls
- Amitriptyline recalls (updated)
- Angiotensin receptor blockers (ARB) recalls
- Betahistine recalls (new)
- Cinacalcet recalls (new)
- Duloxetine recalls
- Folic Acid recalls (new)
- Metformin recalls
- Nizatidine recalls
- Orphenadrine recalls
- Propranolol recalls
- Quetiapine recalls (new)
- Quinapril recalls
- Ranitidine recalls
- Sitagliptin recalls (new)
- Varenicline recalls
What you should do
Health products listed on this page have been recalled due to the presence of, or potential for, nitrosamine impurities.
Health products not on the lists below have not been recalled in Canada. Recalls taking place in other countries may not affect Canadian products.
In general, if a prescription drug is recalled, you shouldn't stop taking your prescription medications until you:
- talk to your health care provider first and
- obtain an alternative treatment
Going without treatment for a medical condition may pose a greater health risk than potential nitrosamine exposure.
Speak to your pharmacist to see if the lot of medication you're taking is part of the recall.
For further information, including patient recommendations, that are specific to the recalled products please click on the hyperlinks provided for each recalled health product.
You're encouraged to report a side effect to a drug or complaint to Health Canada.
Acyclovir recalls
| Company | Product Name | DIN | Strength | Lot | Expiry |
|---|---|---|---|---|---|
| Apotex Inc. | Apo-Acyclovir 200 mg | 02207621 | 200 mg | RH9369 | 08/2022 |
| Apotex Inc. | Apo-Acyclovir 200 mg | 02207621 | 200 mg | TF4466 | 08/2024 |
| Apotex Inc. | Apo-Acyclovir 800 mg | 02207656 | 800 mg | TE5062 | 06/2023 |
| Apotex Inc. | Apo-Acyclovir 800 mg | 02207656 | 800 mg | TH6119 | 12/2023 |
| Apotex Inc. | Apo-Acyclovir 200 mg | 02207621 | 200 mg | RH9368 | 08/2022 |
| Apotex Inc. | Apo-Acyclovir 200 mg | 02207621 | 200 mg | RH9370 | 08/2022 |
| Apotex Inc. | Apo-Acyclovir 800 mg | 02207656 | 800 mg | RP8516 | 07/2022 |
| Apotex Inc. | Apo-Acyclovir 800 mg | 02207656 | 800 mg | RP8517 | 07/2022 |
| Apotex Inc. | Apo-Acyclovir 800 mg | 02207656 | 800 mg | RT8943 | 07/2022 |
| Apotex Inc. | Apo-Acyclovir 200 mg | 02207621 | 200 mg | TE5048 | 06/2024 |
| Apotex Inc. | Apo-Acyclovir 200 mg | 02207621 | 200 mg | TK5832 | 05/2025 |
| Apotex Inc. | Apo-Acyclovir 400mg | 02207648 | 400mg | TH6095 | 12/2023 |
| Apotex Inc. | Apo-Acyclovir 400mg | 02207648 | 400mg | TH6096 | 12/2023 |
| Apotex Inc. | Apo-Acyclovir 400mg | 02207648 | 400mg | TH6098 | 12/2023 |
| Apotex Inc. | Apo-Acyclovir 800 mg | 02207656 | 800 mg | TK1734 | 05/2024 |
| Apotex Inc. | Apo-Acyclovir 800 mg | 02207656 | 800 mg | TK3921 | 05/2024 |
Communications related to acyclovir recalls:
- Apotex recalls Apo-Acyclovir tablets due to a nitrosamine impurity (July 28, 2022)
- Apo-Acyclovir Tablets: NDMA impurity (Updated with new product and lot numbers) - Canada.ca
Amitriptyline recalls
| Company | Product name | DIN | Strength | Lot | Expiry |
|---|---|---|---|---|---|
| AA Pharma | Elavil | 00335053 | 10 mg | RW8596 | 11/2025 |
| AA Pharma | Elavil | 00335053 | 10 mg | TF8594 | 08/2026 |
| AA Pharma | Elavil | 00335053 | 10 mg | TF8597 | 08/2026 |
| AA Pharma | Elavil | 00335061 | 25 mg | TF8600 | 08/2026 |
| Apotex Inc. | APO-Amitriptyline | 02403137 | 10 mg | RN6384 | 03/2025 |
| Apotex Inc. | APO-Amitriptyline | 02403137 | 10 mg | RR0265 | 03/2025 |
| Apotex Inc. | APO-Amitriptyline | 02403137 | 10 mg | RR0266 | 03/2025 |
| Apotex Inc. | APO-Amitriptyline | 02403137 | 10 mg | RV1644 | 08/2025 |
| Apotex Inc. | APO-Amitriptyline | 02403137 | 10 mg | RV1645 | 08/2025 |
| Apotex Inc. | APO-Amitriptyline | 02403137 | 10 mg | RW8597 | 11/2025 |
| Apotex Inc. | APO-Amitriptyline | 02403137 | 10 mg | RW8598 | 11/2025 |
| Apotex Inc. | APO-Amitriptyline | 02403137 | 10 mg | TA6008 | 02/2026 |
| Apotex Inc. | APO-Amitriptyline | 02403137 | 10 mg | TA6009 | 01/2026 |
| Apotex Inc. | APO-Amitriptyline | 02403137 | 10 mg | TF8585 | 08/2026 |
| Apotex Inc. | APO-Amitriptyline | 02403137 | 10 mg | TF8586 | 07/2026 |
| Apotex Inc. | APO-Amitriptyline | 02403137 | 10 mg | TF8587 | 08/2026 |
| Apotex Inc. | APO-Amitriptyline | 02403137 | 10 mg | TF8588 | 07/2026 |
| Apotex Inc. | APO-Amitriptyline | 02403137 | 10 mg | TF8589 | 07/2026 |
| Apotex Inc. | APO-Amitriptyline | 02403137 | 10 mg | TW2842 | 06/2025 |
| Apotex Inc. | APO-Amitriptyline | 02403137 | 10 mg | TW2843 | 06/2025 |
| Apotex Inc. | APO-Amitriptyline | 02403137 | 25 mg | RM0519 | 11/2024 |
| Apotex Inc. | APO-Amitriptyline | 02403137 | 25 mg | RM8130 | 11/2024 |
| Apotex Inc. | APO-Amitriptyline | 02403137 | 25 mg | RR0780 | 03/2025 |
| Apotex Inc. | APO-Amitriptyline | 02403137 | 25 mg | RR0781 | 03/2025 |
| Apotex Inc. | APO-Amitriptyline | 02403137 | 25 mg | RV1656 | 08/2025 |
| Apotex Inc. | APO-Amitriptyline | 02403137 | 25 mg | RV1657 | 08/2025 |
| Apotex Inc. | APO-Amitriptyline | 02403137 | 25 mg | RW8691 | 10/2025 |
| Apotex Inc. | APO-Amitriptyline | 02403137 | 25 mg | TA6061 | 02/2026 |
| Apotex Inc. | APO-Amitriptyline | 02403137 | 25 mg | TA6062 | 02/2026 |
| Apotex Inc. | APO-Amitriptyline | 02403137 | 25 mg | TF8602 | 08/2026 |
| Apotex Inc. | APO-Amitriptyline | 02403137 | 25 mg | TF8603 | 08/2026 |
| Apotex Inc. | APO-Amitriptyline (Amitriptyline Hydrochloride Tablets USP) | 02403137 | 10 mg | RF0410 | 05/2024 |
| Apotex Inc. | APO-Amitriptyline (Amitriptyline Hydrochloride Tablets USP) | 02403137 | 10 mg | PY1831 | 12/2023 |
| Apotex Inc. | APO-Amitriptyline (Amitriptyline Hydrochloride Tablets USP) | 02403137 | 10 mg | PY1832 | 12/2023 |
| Apotex Inc. | APO-Amitriptyline (Amitriptyline Hydrochloride Tablets USP) | 02403137 | 10 mg | PY1904 | 12/2023 |
| AA Pharma Inc. | Elavil (Amitriptyline Hydrochloride Tablets USP) | 00335053 | 10 mg | PY1829 | 12/2023 |
| AA Pharma Inc. | Elavil (Amitriptyline Hydrochloride Tablets USP) | 00335053 | 10 mg | PY1830 | 12/2023 |
| AA Pharma Inc. | Elavil (Amitriptyline Hydrochloride Tablets USP) | 00335061 | 25 mg | PV0570 | 11/2023 |
| AA Pharma Inc. | Elavil (Amitriptyline Hydrochloride Tablets USP) | 00335061 | 25 mg | PV0571 | 11/2023 |
| Apotex Inc. | APO-Amitriptyline (Amitriptyline Hydrochloride Tablets USP) | 02403137 | 10 mg | PY1833 | 12/2023 |
| Apotex Inc. | APO-Amitriptyline (Amitriptyline Hydrochloride Tablets USP) | 02403137 | 10 mg | RM0518 | 11/2024 |
| Apotex Inc. | APO-Amitriptyline (Amitriptyline Hydrochloride Tablets USP) | 02403145 | 25 mg | PV0569 | 11/2023 |
| Pharmascience Inc. | PMS- Amitriptyline | 00654523 | 10 mg | 635484 | 04/2024 |
| Pharmascience Inc. | PMS- Amitriptyline | 00654523 | 10 mg | 638600 | 07/2024 |
| Pharmascience Inc. | PMS- Amitriptyline | 00654523 | 10 mg | 636906 | 07/2024 |
| Pharmascience Inc. | PMS- Amitriptyline | 00654523 | 10 mg | 636907 | 07/2024 |
| Pharmascience Inc. | PMS- Amitriptyline | 00654523 | 10 mg | 648428 | 04/2026 |
| Pharmascience Inc. | PMS- Amitriptyline | 00654523 | 10 mg | 648429 | 04/2026 |
| Pharmascience Inc. | PMS- Amitriptyline | 00654523 | 10 mg | 633439 | 01/2024 |
| Pharmascience Inc. | PMS- Amitriptyline | 00654523 | 10 mg | 632625 | 12/2023 |
| Pharmascience Inc. | PMS- Amitriptyline | 00654523 | 10 mg | 632626 | 12/2023 |
| Pharmascience Inc. | PMS- Amitriptyline | 00654523 | 10 mg | 633440 | 01/2024 |
| Pharmascience Inc. | PMS- Amitriptyline | 00654523 | 10 mg | 636905 | 07/2024 |
| Pharmascience Inc. | PMS- Amitriptyline | 00654523 | 10 mg | 636146 | 06/2024 |
| Pharmascience Inc. | PMS- Amitriptyline | 00654523 | 10 mg | 636749 | 07/2024 |
| Pharmascience Inc. | PMS- Amitriptyline | 00654523 | 10 mg | 634973 | 03/2024 |
| Pharmascience Inc. | PMS- Amitriptyline | 00654523 | 10 mg | 635485 | 04/2024 |
| Pharmascience Inc. | PMS- Amitriptyline | 00654515 | 25 mg | 635435 | 04/2024 |
| Pharmascience Inc. | PMS- Amitriptyline | 00654515 | 25 mg | 633433 | 01/2024 |
| Pharmascience Inc. | PMS- Amitriptyline | 00654515 | 25 mg | 632775 | 23/2023 |
| Pharmascience Inc. | PMS- Amitriptyline | 00654515 | 25 mg | 635482 | 05/2024 |
| Pharmascience Inc. | PMS- Amitriptyline | 00654507 | 50 mg | 634972 | 03/2024 |
| Pharmascience Inc. | PMS- Amitriptyline | 00654507 | 50 mg | 635465 | 05/2024 |
| Pharmascience Inc. | PMS- Amitriptyline | 00654507 | 50 mg | 637195 | 08/2024 |
| Pharmascience Inc. | PMS- Amitriptyline | 00654507 | 50 mg | 637532 | 09/2024 |
| Pro Doc Limitée | Amitriptyline-10 | 00370991 | 10 mg | 632627 | 12/2023 |
| Pro Doc Limitée | Amitriptyline-10 | 00370991 | 10 mg | 633441 | 01/2024 |
| Pro Doc Limitée | Amitriptyline-10 | 00370991 | 10 mg | 638164 | 10/2024 |
| Pro Doc Limitée | Amitriptyline-50 | 00456349 | 50 mg | 633436 | 01/2024 |
Communications related to amitriptyline recalls:
- Amitriptyline antidepressant drugs recalled because of a nitrosamine impurity ( February 7, 2023)
- Apo-Amitriptyline: Affected lots may exceed the interim acceptable intake limit for NNORT - Canada.ca
- Elavil: Affected lots may exceed the interim acceptable intake limit for NNORT - Canada.ca
- APO-AMITRIPTYLINE Tablets: NNORT impurity
- AMITRIPTYLINE 10 & 50mg: NDMA and NNORT impurity
- PMS-AMITRIPTYLINE 10 mg, 25 mg, and 50 mg: NDMA and NNORT impurity
- APO-AMITRIPTYLINE 10mg: NDMA Impurity
- APO-AMITRIPTYLINE 10mg: NDMA impurity
- Elavil 25 mg: NNORT Impurity
- ELAVIL 10mg: NDMA impurity
Angiotensin receptor blockers (ARBs) recalls
| Product name | DIN | Strength | Lot # | Date recalled | API manufacturer |
|---|---|---|---|---|---|
| AURO-IRBESARTAN/HCT | 02447878 | 150/12.5 mg | IN1518001-A | April 17, 2019 | Aurobindo Pharma Limited, Unit-I |
| IRBESARTAN (PRO DOC LIMITEE) | 02365200 | 150 mg | 604292 | March 11, 2019 | TEVA API India Ltd. |
| IRBESARTAN (PRO DOC LIMITEE) | 02365219 | 300 mg | 601795 | March 11, 2019 | TEVA API India Ltd. |
| APO-LOSARTAN | 02379058 | 25 mg | NL1453 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
| APO-LOSARTAN | 02379058 | 25 mg | NL1452 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
| APO-LOSARTAN | 02353504 | 50 mg | NK1254 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
| APO-LOSARTAN | 02353504 | 50 mg | NK1253 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
| APO-LOSARTAN | 02353512 | 100 mg | NL1461 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
| APO-LOSARTAN | 02353512 | 100 mg | NG2092 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
| APO-LOSARTAN | 02353512 | 1 00 mg | NH5932 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
| APO-LOSARTAN | 02353512 | 100 mg | NH5933 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
| APO-LOSARTAN | 02353512 | 100 mg | NL1460 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
| APO-LOSARTAN | 02353512 | 100 mg | NH5934 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
| APO-LOSARTAN/HCTZ | 02371235 | 50/12.5 mg | NL1441 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
| APO-LOSARTAN/HCTZ | 02371235 | 50/12.5 mg | NZ8848 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
| APO-LOSARTAN/HCTZ | 02371235 | 50/12.5 mg | NL1445 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
| APO-LOSARTAN/HCTZ | 02371235 | 50/12.5 mg | NZ8849 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
| APO-LOSARTAN/HCTZ | 02371235 | 50/12.5 mg | NZ8860 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
| APO-LOSARTAN/HCTZ | 02371243 | 100/12.5 mg | NG2087 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
| APO-LOSARTAN/HCTZ | 02371243 | 100/12.5 mg | NL1421 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
| APO-LOSARTAN/HCTZ | 02371243 | 100/12.5 mg | NG2086 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
| APO-LOSARTAN/HCTZ | 02371243 | 100/12.5 mg | NL1422 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
| APO-LOSARTAN/HCTZ | 02371251 | 100/25 mg | NL1429 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
| APO-LOSARTAN/HCTZ | 02371251 | 100/25 mg | NZ8846 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
| APO-LOSARTAN/HCTZ | 02371251 | 100/25 mg | NZ8847 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
| APO-LOSARTAN/HCTZ | 02371251 | 100/25 mg | NZ8845 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
| PMS-LOSARTAN | 02309750 | 25 mg | 498294 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
| PMS-LOSARTAN | 02309750 | 25 mg | 605342 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
| PMS-LOSARTAN | 02309750 | 25 mg | 611944 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
| PMS-LOSARTAN | 02309769 | 50 mg | 498285 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
| PMS-LOSARTAN | 02309769 | 50 mg | 600047 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
| PMS-LOSARTAN | 02309769 | 50 mg | 600091 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
| PMS-LOSARTAN | 02309769 | 50 mg | 603894 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
| PMS-LOSARTAN | 02309769 | 50 mg | 612025 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
| PMS-LOSARTAN | 02309769 | 50 mg | 612031 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
| PMS-LOSARTAN | 02309769 | 50 mg | 612679 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
| PMS-LOSARTAN | 02309769 | 50 mg | 616743 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
| PMS-LOSARTAN | 02309777 | 100 mg | 498864 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
| PMS-LOSARTAN | 02309777 | 100 mg | 602668 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
| PMS-LOSARTAN | 02309777 | 100 mg | 603816 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
| PMS-LOSARTAN | 02309777 | 100 mg | 605298 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
| PMS-LOSARTAN | 02309777 | 100 mg | 605300 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
| PMS-LOSARTAN | 02309777 | 100 mg | 613935 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
| PMS-LOSARTAN | 02309777 | 100 mg | 613936 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
| LOSARTAN (PRO DOC LIMITEE) | 02394367 | 25 mg | 498292 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
| LOSARTAN (PRO DOC LIMITEE) | 02394367 | 25 mg | 605344 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
| LOSARTAN (PRO DOC LIMITEE) | 02394375 | 50 mg | 498779 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
| LOSARTAN (PRO DOC LIMITEE) | 02394375 | 50 mg | 600046 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
| LOSARTAN (PRO DOC LIMITEE) | 02394375 | 50 mg | 603903 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
| LOSARTAN (PRO DOC LIMITEE) | 02394375 | 50 mg | 498284 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
| LOSARTAN (PRO DOC LIMITEE) | 02394375 | 50 mg | 603895 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
| LOSARTAN (PRO DOC LIMITEE) | 02394383 | 100 mg | 499008 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
| LOSARTAN (PRO DOC LIMITEE) | 02394383 | 100 mg | 605299 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
| LOSARTAN (PRO DOC LIMITEE) | 02394383 | 100 mg | 605297 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
| TEVA-LOSARTAN/HCTZ | 02358263 | 50/12.5 mg | 35344801A | March 6, 2019 | Hetero Laboratories Limited Unit 1 |
| TEVA-LOSARTAN/HCTZ | 02358263 | 50/12.5mg | 35349397A | March 6, 2019 | Hetero Laboratories Limited Unit 1 |
| MYLAN-VALSARTAN | 02383527 | 40 mg | All lots | November 28, 2018 | Mylan Laboratories Limited |
| MYLAN-VALSARTAN | 02383535 | 80 mg | All lots | November 28, 2018 | Mylan Laboratories Limited |
| MYLAN-VALSARTAN | 02383543 | 160 mg | All lots | November 28, 2018 | Mylan Laboratories Limited |
| MYLAN-VALSARTAN | 02383551 | 3 20 mg | All lots | November 28, 2018 | Mylan Laboratories Limited |
| TEVA-VALSARTAN/HCTZ TABLETS | 02356996 | 80/12.5 mg | 35211136A | August 17, 2018 | Zhejiang Huahai Pharmaceuticals |
| TEVA-VALSARTAN/HCTZ TABLETS | 02357003 | 160/12.5 mg | 35211335A | August 17, 2018 | Zhejiang Huahai Pharmaceuticals |
| TEVA-VALSARTAN/HCTZ TABLETS | 02357003 | 160/12.5 mg | 35211844R | August 17, 2018 | Zhejiang Huahai Pharmaceuticals |
| TEVA-VALSARTAN/HCTZ TABLETS | 02357011 | 160/25 mg | 35210937R | August 17, 2018 | Zhejiang Huahai Pharmaceuticals |
| TEVA-VALSARTAN/HCTZ TABLETS | 02357011 | 160/25 mg | 35210938R | August 17, 2018 | Zhejiang Huahai Pharmaceuticals |
| TEVA-VALSARTAN/HCTZ TABLETS | 02357011 | 160/25 mg | 35210939R | August 17, 2018 | Zhejiang Huahai Pharmaceuticals |
| TEVA-VALSARTAN/HCTZ TABLETS | 02357011 | 160/25 mg | 35210940R | August 17, 2018 | Zhejiang Huahai Pharmaceuticals |
| TEVA-VALSARTAN/HCTZ TABLETS | 02357038 | 3 20/12.5 mg | 35211546R | August 17, 2018 | Zhejiang Huahai Pharmaceuticals |
| ACT-VALSARTAN | 02337487 | 40 mg | K47338 | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
| ACT-VALSARTAN | 02337495 | 80 mg | K45370 | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
| ACT-VALSARTAN | 02337495 | 80 mg | K47652 | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
| ACT-VALSARTAN | 02337495 | 80 mg | K47653 | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
| ACT-VALSARTAN | 02337495 | 80mg | K47654 | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
| ACT-VALSARTAN | 02337509 | 160 mg | K39691 | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
| ACT-VALSARTAN | 02337509 | 160 mg | K44167 | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
| ACT-VALSARTAN | 02337509 | 160 mg | K47657 | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
| ACT-VALSARTAN | 02337509 | 160 mg | K47658 | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
| ACT-VALSARTAN | 02337517 | 320 mg | K44166 | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
| ACT-VALSARTAN | 02337517 | 320 mg | K45371 | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
| VALSARTAN (PRO DOC LIMITEE) | 02367726 | 40 mg | All lots | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
| VALSARTAN (PRO DOC LIMITEE) | 02367734 | 80 mg | All lots | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
| VALSARTAN (PRO DOC LIMITEE) | 02367742 | 160 mg | All lots | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
| VALSARTAN (PRO DOC LIMITEE) | 02367750 | 320 mg | All lots | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
| SANDOZ VALSARTAN | 02356740 | 40 mg | All lots | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
| SANDOZ VALSARTAN | 02356759 | 80 mg | All lots | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
| SANDOZ VALSARTAN | 02356767 | 160 mg | All lots | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
| SANDOZ VALSARTAN | 02356775 | 320 mg | All lots | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
| SANIS VALSARTAN | 02366940 | 40 mg | All lots | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
| SANIS VALSARTAN | 02366959 | 80 mg | All lots | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
| SANIS VALSARTAN | 02366967 | 160 mg | All lots | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
| SANIS VALSARTAN | 02366975 | 320 mg | All lots | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
| VALSARTAN (SIVEM PHARMACEUTICAL ULC) | 02384523 | 40 mg | All lots | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
| VALSARTAN (SIVEM PHARMACEUTICAL ULC) | 02384531 | 80 mg | All lots | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
| VALSARTAN (SIVEM PHARMACEUTICAL ULC) | 02384558 | 160 mg | All lots | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
| VALSARTAN (SIVEM PHARMACEUTICAL ULC) | 02384566 | 320 mg | All lots | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
| TEVA-VALSARTAN/HCTZ | 02357046 | 320/25 mg | 35212731R | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
Communications related to ARB recalls:
- Auro Pharma Inc. voluntarily recalls one lot of Auro-Irbesartan HCT tablets because of nitrosamine impurity (information update April 4, 2019)
- Pro Doc Limitée voluntarily recalls two lots of irbesartan drugs because of nitrosamine impurity (information update, March 14, 2019)
- Multiple Losartan-containing drugs voluntarily recalled because of potential for nitrosamine impurity (information update March 9, 2019)
- Health Canada releases test results of certain sartan drugs (information update December 20, 2018)
- Mylan-Valsartan medications voluntarily recalled as a precaution due to an impurity (information update November 28, 2018)
- Health Canada finds Zhejiang Huahai Pharmaceuticals site non-compliant with requirements for the manufacture of drug ingredients (information update October 2, 2018)
- Health Canada advises of a second impurity linked to recalled valsartan drugs (information update September 13, 2018)
- Health Canada updates Canadians on estimates of health risks for recalled valsartan drugs containing NDMA (information update September 10, 2018)
- Teva Canada expands recall of valsartan drugs to include additional lots, as a precaution (information update August 18, 2018)
- Several drugs containing valsartan being recalled due to contamination with a potential carcinogen (advisory July 9, 2018)
Betahistine recalls
| Company | Product Name | DIN | Strength | Lot | Expiry |
|---|---|---|---|---|---|
| Teva Canada Ltd. | TEVA-Betahistine | 02280183 | 8 mg | 100043755 |
03/31/2025 |
| Teva Canada Ltd. | TEVA-Betahistine | 02280183 | 8 mg | 100047041 |
10/31/2025 |
| Teva Canada Ltd. | TEVA-Betahistine | 02280183 | 8 mg | 100054115 |
01/31/2026 |
| Teva Canada Ltd. | TEVA-Betahistine | 02280183 | 8 mg | 100057407 |
06/30/2026 |
| Teva Canada Ltd. | TEVA-Betahistine | 02280191 | 16 mg | 100039202 |
12/31/2024 |
| Teva Canada Ltd. | TEVA-Betahistine | 02280191 | 16 mg | 100039975 | 03/31/2025 |
| Teva Canada Ltd. | TEVA-Betahistine | 02280191 | 16 mg | 100040342 | 03/31/2025 |
| Teva Canada Ltd. | TEVA-Betahistine | 02280191 | 16 mg | 100047037 | 06/30/2025 |
| Teva Canada Ltd. | TEVA-Betahistine | 02280191 | 16 mg | 100047038 | 09/30/2025 |
| Teva Canada Ltd. | TEVA-Betahistine | 02280191 | 16 mg | 100048555 | 09/30/2025 |
| Teva Canada Ltd. | TEVA-Betahistine | 02280191 | 16 mg | 100050930 | 09/30/2025 |
| Teva Canada Ltd. | TEVA-Betahistine | 02280191 | 16 mg | 100052559 | 02/28/2026 |
| Teva Canada Ltd. | TEVA-Betahistine | 02280191 | 16 mg | 100057107 | 01/31/2026 |
| Teva Canada Ltd. | TEVA-Betahistine | 02280191 | 16 mg | 100057408 | 03/31/2026 |
| Teva Canada Ltd. | TEVA-Betahistine | 02280191 | 16 mg | 100058036 | 06/30/2026 |
| Teva Canada Ltd. | TEVA-Betahistine | 02280191 | 16 mg | 100062444 | 08/31/2026 |
| Teva Canada Ltd. | TEVA-Betahistine | 02280191 | 16 mg | 100038357 | 03/31/2025 |
| Teva Canada Ltd. | TEVA-Betahistine | 02280191 | 16 mg | 100047367 | 09/30/2025 |
| Teva Canada Ltd. | TEVA-Betahistine | 02280205 | 24 mg | 100038340 | 03/31/2025 |
| Teva Canada Ltd. | TEVA-Betahistine | 02280205 | 24 mg | 100043738 | 03/31/2025 |
| Teva Canada Ltd. | TEVA-Betahistine | 02280205 | 24 mg | 100049891 | 09/30/2025 |
| Teva Canada Ltd. | TEVA-Betahistine | 02280205 | 24 mg | 100052857 | 04/30/2026 |
| Teva Canada Ltd. | TEVA-Betahistine | 02280205 | 24 mg | 100056000 | 04/30/2026 |
| Teva Canada Ltd. | TEVA-Betahistine | 02280205 | 24 mg | 100039609 | 03/31/2025 |
| Teva Canada Ltd. | TEVA-Betahistine | 02280205 | 24 mg | 100039610 | 03/31/2025 |
| Teva Canada Ltd. | TEVA-Betahistine | 02280205 | 24 mg | 100039611 | 03/31/2025 |
| Teva Canada Ltd. | TEVA-Betahistine | 02280205 | 24 mg | 100044222 | 03/31/2025 |
| Teva Canada Ltd. | TEVA-Betahistine | 02280205 | 24 mg | 100049365 | 09/30/2025 |
| Teva Canada Ltd. | TEVA-Betahistine | 02280205 | 24 mg | 100058037 |
04/30/2026 |
| Sanis Health Inc. | Betahistine | 02466449 | 16 mg | 100039203 | 03/2025 |
| Sanis Health Inc. | Betahistine | 02466449 | 16 mg | 100047036 | 06/2025 |
| Sanis Health Inc. | Betahistine | 02466449 | 16 mg | 100053524 | 01/2026 |
| Sanis Health Inc. | Betahistine | 02466449 | 16 mg | 100059890 | 06/2026 |
| Sanis Health Inc. | Betahistine | 02466449 | 16 mg | 100062445 | 08/2026 |
| Sanis Health Inc. | Betahistine | 02466457 | 24 mg | 100039462 | 03/2025 |
| Sanis Health Inc. | Betahistine | 02466457 | 24 mg | 100049894 | 09/2025 |
Communications related to Betahistine recalls:
- TEVA-Betahistine Tablets: Affected lots exceed or may exceed the interim acceptable intake limit for N-nitroso-betahistine.
- BETAHISTINE: Affected lots exceed or may exceed the interim acceptable intake limit for N-nitroso-betahistine.
Cinacalcet recalls
| Company | Product Name | DIN | Strength | Lot | Expiry |
|---|---|---|---|---|---|
| Pharmascience Inc. | PMS-Cinacalcet | 02517604 | 30 mg | T2304707 | 08/2025 |
| Pharmascience Inc. | PMS-Cinacalcet | 02517612 | 60 mg | T2304708 | 08/2025 |
| Pharmascience Inc. | PMS-Cinacalcet | 02517620 | 90 mg | T2304718 | 08/2025 |
| Amgen Canada Inc. | Sensipar | 02257130 | 30mg | 1163742 | 02/29/28 |
| Amgen Canada Inc. | Sensipar | 02257130 | 30mg | 1153664 | 10/31/26 |
| Amgen Canada Inc. | Sensipar | 02257130 | 30mg | 1140611 | 07/31/25 |
| Amgen Canada Inc. | Sensipar | 02257130 | 30mg | 1132162 | 06/30/25 |
| Amgen Canada Inc. | Sensipar | 02257130 | 30mg | 1118138 | 06/30/25 |
| Amgen Canada Inc. | Sensipar | 02257130 | 30mg | 1122255 | 05/31/25 |
| Amgen Canada Inc. | Sensipar | 02257149 | 60mg | 1171343 | 12/31/27 |
| Amgen Canada Inc. | Sensipar | 02257149 | 60mg | 1162328 | 02/29/28 |
| Amgen Canada Inc. | Sensipar | 02257149 | 60mg | 1146254 | 01/31/26 |
| Amgen Canada Inc. | Sensipar | 02257149 | 60mg | 1140612 | 01/31/26 |
| Amgen Canada Inc. | Sensipar | 02257149 | 60mg | 1133461 | 01/31/26 |
| Amgen Canada Inc. | Sensipa | 02257157 | 90mg | 1123149 | 06/30/25 |
| Amgen Canada Inc. | Sensipar | 02257157 | 90mg | 1118135 | 06/30/25 |
Communications related to Cinacalcet recalls:
- PMS-CINACALCET: Affected lots may exceed the established acceptable intake limit for N-nitroso-cinacalcet.
- Sensipar (30mg, 60mg, 90mg): Levels of N-nitroso-cinacalcet exceeding the established acceptable intake (AI) limits in affected lots. - Canada.ca
Duloxetine recalls
| Company | Product Name | DIN | Strength | Lot | Expiry |
|---|---|---|---|---|---|
| Pharmascience Inc. | PMS-Duloxetine | 02429446 | 30 MG | 646038 | 31/01/2025 |
| Pharmascience Inc. | PMS-Duloxetine | 02429454 | 60 MG | 642678 | 30/04/2024 |
| Pharmascience Inc. | PMS-Duloxetine | 02429454 | 60 MG | 645166 | 31/01/2025 |
| Pharmascience Inc. | PMS-Duloxetine | 02429454 | 60 MG | 646571 | 31/01/2025 |
| Sanis Health Inc. | Duloxetine | 02490897 | 60 MG | 644182 | 30/09/2024 |
Communications related to duloxetine recalls:
- Sanis Health Duloxetine 60 mg Capsule; Exceeds acceptable interim intake limit for N-nitroso-duloxetine (NDLX)
- PMS-Duloxetine 60 mg: Exceeds acceptable interim intake limit for N-nitroso-duloxetine (NDLX)
- PMS-Duloxetine 30 mg: Exceeds acceptable interim intake limit for N-nitroso-duloxetine (NDLX)
Folic Acid recalls
| Company | Product Name | DIN | Strength | Lot | Expiry |
|---|---|---|---|---|---|
| JAMP Pharma Corporation | Pregnancy Multivitamin | 02535718 | Blue tablets only: Folic acid 1.1 mg / Vitamin B12 12 mcg / Vitamin D3 600 IU / Calcium 300 mg | LKE05 | 04/2025 |
| JAMP Pharma Corporation | Pregnancy Multivitamin | 02535718 | Blue tablets only: Folic acid 1.1 mg / Vitamin B12 12 mcg / Vitamin D3 600 IU / Calcium 300 mg | LKE07 | 05/2025 |
| JAMP Pharma Corporation | Pregnancy Multivitamin | 02535718 | Blue tablets only: Folic acid 1.1 mg / Vitamin B12 12 mcg / Vitamin D3 600 IU / Calcium 300 mg | LKE08 | 05/2025 |
| JAMP Pharma Corporation | Pregnancy Multivitamin | 02535718 | Blue tablets only: Folic acid 1.1 mg / Vitamin B12 12 mcg / Vitamin D3 600 IU / Calcium 300 mg | LKE09 | 05/2025 |
| JAMP Pharma Corporation | Pregnancy Multivitamin Folic 5 | 02537478 | Dark Blue tablets only: Folic acid 5 mg / Vitamin B12 12 mcg / Vitamin D3 600 IU / Calcium 300 mg |
LKE10 | 04/2025 |
| JAMP Pharma Corporation | Pregnancy Multivitamin Folic 5 | 02537478 | Dark Blue tablets only: Folic acid 5 mg / Vitamin B12 12 mcg / Vitamin D3 600 IU / Calcium 300 mg |
LKE11 | 04/2025 |
| JAMP Pharma Corporation | Pregnancy Multivitamin Folic 5 | 02537478 | Dark Blue tablets only: Folic acid 5 mg / Vitamin B12 12 mcg / Vitamin D3 600 IU / Calcium 300 mg |
LKE14 | 05/2025 |
Communications related to Folic Acid recalls:
Metformin recalls
| Company | Product name | DIN | Strength | Lot | Expiry |
|---|---|---|---|---|---|
| Apotex Inc. | APO-Metformin ER (Metformin Hydrochloride Extended-Release Tablets) | 02305062 | 500 mg | NV3242 | 04/2020 |
| Apotex Inc. | APO-Metformin ER (Metformin Hydrochloride Extended-Release Tablets) | 02305062 | 500 mg | NV3244 | 04/2020 |
| Apotex Inc. | APO-Metformin ER (Metformin Hydrochloride Extended-Release Tablets) | 02305062 | 500 mg | NV3245 | 04/2020 |
| Apotex Inc. | APO-Metformin ER (Metformin Hydrochloride Extended-Release Tablets) | 02305062 | 500 mg | NV3243 | 04/2020 |
| Apotex Inc. | APO-Metformin ER (Metformin Hydrochloride Extended-Release Tablets) | 02305062 | 500 mg | NV3247 | 04/2020 |
| Apotex Inc. | APO-Metformin ER (Metformin Hydrochloride Extended-Release Tablets) | 02305062 | 500 mg | NV3248 | 04/2020 |
| Apotex Inc. | APO-Metformin ER (Metformin Hydrochloride Extended-Release Tablets) | 02305062 | 500 mg | PX5334 | 01/2021 |
| Apotex Inc. | APO-Metformin ER (Metformin Hydrochloride Extended-Release Tablets) | 02305062 | 500 mg | PX5335 | 01/2021 |
| Ranbaxy Pharmaceuticals Canada Inc. | RAN-Metformin | 02269031 | 500 mg | AJY8006A | 05/2020 |
| Ranbaxy Pharmaceuticals Canada Inc. | RAN-Metformin | 02269031 | 500 mg | AJY8007A | 05/2020 |
| Ranbaxy Pharmaceuticals Canada Inc. | RAN-Metformin | 02269031 | 500 mg | AJY8005A | 05/2020 |
| Ranbaxy Pharmaceuticals Canada Inc. | RAN-Metformin | 02269031 | 500 mg | AJY8005B | 05/2020 |
| Ranbaxy Pharmaceuticals Canada Inc. | RAN-Metformin | 02269031 | 500 mg | AJY8008A | 05/2020 |
| Ranbaxy Pharmaceuticals Canada Inc. | RAN-Metformin | 02269058 | 850 mg | AJZ8005A | 05/2020 |
| JAMP Pharma | Metformin | 02380196 | 500 mg | X20283 | 11/2020 |
| JAMP Pharma | Metformin | 02380196 | 500 mg | X20284 | 11/2020 |
| JAMP Pharma | Metformin | 02380196 | 500 mg | X20286 | 11/2020 |
| JAMP Pharma | Metformin | 02380196 | 500 mg | X20287 | 11/2020 |
| JAMP Pharma | Metformin | 02380196 | 500 mg | X20288 | 11/2020 |
| JAMP Pharma | Metformin | 02380196 | 500 mg | Y00225 | 12/2020 |
| JAMP Pharma | Metformin | 02380196 | 500 mg | Y00226 | 12/2020 |
| JAMP Pharma | Metformin | 02380196 | 500 mg | Y00227 | 12/2020 |
| JAMP Pharma | Metformin | 02380196 | 500 mg | Y00228 | 01/2021 |
| JAMP Pharma | Metformin | 02380196 | 500 mg | Y00229 | 01/2021 |
| JAMP Pharma | Metformin | 02380196 | 500 mg | Y00230 | 01/2021 |
| JAMP Pharma | Metformin | 02380196 | 500 mg | Y00231 | 05/2021 |
| JAMP Pharma | Metformin | 02380196 | 500 mg | Y00232 | 05/2021 |
| JAMP Pharma | Metformin | 02380196 | 500 mg | Y01573 | 05/2021 |
| JAMP Pharma | Metformin | 02380196 | 500 mg | Y01574 | 05/2021 |
| JAMP Pharma | Metformin | 02380196 | 500 mg | Y01575 | 05/2021 |
| JAMP Pharma | Metformin | 02380196 | 500 mg | Y01576 | 05/2021 |
| JAMP Pharma | Metformin | 02380196 | 500 mg | Y01577 | 05/2021 |
| JAMP Pharma | Metformin | 02380196 | 500 mg | Y01578 | 05/2021 |
| JAMP Pharma | Metformin | 02380196 | 500 mg | Y01579 | 06/2021 |
| JAMP Pharma | Metformin | 02380196 | 500 mg | Y01580 | 06/2021 |
| JAMP Pharma | Metformin | 02380218 | 850 mg | X20385 | 07/2020 |
| JAMP Pharma | Metformin | 02380218 | 850 mg | X20386 | 07/2020 |
| JAMP Pharma | Metformin | 02380218 | 850 mg | X19224 | 10/2020 |
| JAMP Pharma | Metformin | 02380218 | 850 mg | X19225 | 10/2020 |
| JAMP Pharma | Metformin | 02380218 | 850 mg | X19226 | 10/2020 |
| Apotex Inc | APO-METFORMIN ER (Metformin Hydrochloride Extended-Release Tablets) | 02305062 | 500mg | PK3968 | 09/2020 |
| Apotex Inc | APO-METFORMIN ER (Metformin Hydrochloride Extended-Release Tablets) | 02305062 | 500mg | PK3969 | 09/2020 |
| Apotex Inc | APO-METFORMIN ER (Metformin Hydrochloride Extended-Release Tablets) | 02305062 | 500mg | PX5336 | 01/2021 |
| Apotex Inc | APO-METFORMIN ER (Metformin Hydrochloride Extended-Release Tablets) | 02305062 | 500mg | PY7174 | 02/2021 |
| Apotex Inc | APO-METFORMIN ER (Metformin Hydrochloride Extended-Release Tablets) | 02305062 | 500mg | PY7175 | 01/2021 |
| Apotex Inc | APO-METFORMIN ER (Metformin Hydrochloride Extended-Release Tablets) | 02305062 | 500mg | RF6463 | 06/2021 |
| Apotex Inc | APO-METFORMIN ER (Metformin Hydrochloride Extended-Release Tablets) | 02305062 | 500mg | RF6464 | 06/2021 |
| Apotex Inc | APO-METFORMIN ER (Metformin Hydrochloride Extended-Release Tablets) | 02305062 | 500mg | RF6465 | 06/2021 |
| Apotex Inc | APO-METFORMIN ER (Metformin Hydrochloride Extended-Release Tablets) | 02305062 | 500mg | RF6466 | 06/2021 |
Communications related to metformin recalls:
- Health Canada evaluating NDMA in metformin drugs (December 5, 2019)
- Certain Metformin diabetes drugs recalled due to the presence or possible presence of NDMA (February 5, 2020)
Nizatidine recalls
| Company | Product Name | DIN | Strength | Lot | Expiry |
|---|---|---|---|---|---|
| Pendopharm Division of Pharmascience Inc. | AXID | 00778338 | 150mg | 616927 | 31-08-2020 |
| Pendopharm Division of Pharmascience Inc. | AXID | 00778338 | 150mg | 617088 | 31-08-2020 |
Communications related to nizatidine recalls:
Orphenadrine recalls
| Company | Product name | DIN | Strength | Lot | Expiry |
|---|---|---|---|---|---|
| SteriMax Inc. | OrfenAce tablets | 02047535 | 100 mg | 10025A18 | 06/2021 |
| SteriMax Inc. | OrfenAce tablets | 02047535 | 100 mg | 10025B18 | 09/2021 |
| SteriMax Inc. | OrfenAce tablets | 02047535 | 100 mg | 10025A19 | 11/2021 |
| SteriMax Inc. | OrfenAce tablets | 02047535 | 100 mg | 36664 | 6/2021 |
| SteriMax Inc. | OrfenAce tablets | 02047535 | 100 mg | 37342 | 9/2021 |
| SteriMax Inc. | OrfenAce tablets | 02047535 | 100 mg | 37384 | 9/2021 |
| SteriMax Inc. | OrfenAce tablets | 02047535 | 100 mg | 38058 | 11/2021 |
| Sandoz Canada Inc. | Sandoz Orphenadrine tablets | 02243559 | 100 mg | JY6254 | 3/2022 |
| Sandoz Canada Inc. | Sandoz Orphenadrine tablets | 02243559 | 100 mg | JY6255 | 3/2022 |
Communications related to orphenadrine recalls:
Propranolol recalls
| Company | Product name | DIN | Strength | Lot | Expiry |
|---|---|---|---|---|---|
| Pfizer Canada ULC | Inderal-LA capsules | 02042231 | 60 mg | EX7461 | 01/2024 |
| Pfizer Canada ULC | Inderal-LA capsules | 02042231 | 60 mg | EH5907 | 08/2023 |
| Pfizer Canada ULC | Inderal-LA capsules | 02042231 | 60 mg | DX6150 | 03/2023 |
| Pfizer Canada ULC | Inderal-LA capsules | 02042258 | 80 mg | EX7462 | 01/2024 |
| Pfizer Canada ULC | Inderal-LA capsules | 02042258 | 80 mg | EL1695 | 08/2023 |
| Pfizer Canada ULC | Inderal-LA capsules | 02042258 | 80 mg | EE7221 | 05/2023 |
| Pfizer Canada ULC | Inderal-LA capsules | 02042258 | 80 mg | DW8242 | 03/2023 |
| Pfizer Canada ULC | Inderal-LA capsules | 02042258 | 80 mg | DJ2768 | 09/2023 |
| Pfizer Canada ULC | Inderal-LA capsules | 02042266 | 120 mg | FE0541 | 01/2024 |
| Pfizer Canada ULC | Inderal-LA capsules | 02042266 | 120 mg | EH5908 | 08/2023 |
| Pfizer Canada ULC | Inderal-LA capsules | 02042266 | 120 mg | DX6159 | 03/2023 |
| Pfizer Canada ULC | Inderal-LA capsules | 02042266 | 120 mg | DJ6820 | 09/2022 |
| Pfizer Canada ULC | Inderal-LA capsules | 02042274 | 160 mg | FE6304 | 01/2024 |
| Pfizer Canada ULC | Inderal-LA capsules | 02042274 | 160 mg | EH5906 | 08/2023 |
| Pfizer Canada ULC | Inderal-LA capsules | 02042274 | 160 mg | DW8241 | 03/2023 |
Communications related to propranolol recalls:
Quetiapine recalls
| Company | Product Name | DIN | Strength | Lot | Expiry |
|---|---|---|---|---|---|
| Sivem Pharmaceuticals ULC | Quetiapine XR | 02417359 | 50 mg | M2213000 | 08/2025 |
| Sivem Pharmaceuticals ULC | Quetiapine XR | 02417359 | 50 mg | M2213001 | 08/2025 |
| Sivem Pharmaceuticals ULC | Quetiapine XR | 02417359 | 50 mg | M2215146 | 09/2025 |
| Sivem Pharmaceuticals ULC | Quetiapine XR | 02417359 | 50 mg | M2214004 | 09/2025 |
| Sivem Pharmaceuticals ULC | Quetiapine XR | 02417359 | 50 mg | M2214005 | 09/2025 |
| Sivem Pharmaceuticals ULC | Quetiapine XR | 02417367 | 150 mg | M2214685 | 10/2025 |
| Sivem Pharmaceuticals ULC | Quetiapine XR | 02417367 | 150 mg | M2214686 | 10/2025 |
| Sivem Pharmaceuticals ULC | Quetiapine XR | 02417367 | 150 mg | M2214687 | 10/2025 |
| Sivem Pharmaceuticals ULC | Quetiapine XR | 02417375 | 200 mg | M2214012 | 10/2025 |
| Sivem Pharmaceuticals ULC | Quetiapine XR | 02417375 | 200 mg | M2214013 | 10/2025 |
| Sivem Pharmaceuticals ULC | Quetiapine XR | 02417375 | 200 mg | M2214014 | 10/2025 |
| Sivem Pharmaceuticals ULC | Quetiapine XR | 02417383 | 300 mg | M2214016 | 10/2025 |
| Sivem Pharmaceuticals ULC | Quetiapine XR | 02417383 | 300 mg | M2214017 | 10/2025 |
| Sivem Pharmaceuticals ULC | Quetiapine XR | 02417383 | 300 mg | M2214018 | 10/2025 |
| Sivem Pharmaceuticals ULC | Quetiapine XR | 02417391 | 400 mg | M2214020 | 10/2025 |
| Apotex Inc. | Apo-Quetiapine XR | 02457229 | 50 mg | M2213002 | 08/2025 |
| Apotex Inc. | Apo-Quetiapine XR | 02457229 | 50 mg | M2213003 | 08/2025 |
| Apotex Inc. | Apo-Quetiapine XR | 02457229 | 50 mg | M2214445 | 08/2025 |
| Apotex Inc. | Apo-Quetiapine XR | 02457245 | 200 mg | M2214011 | 10/2025 |
| Apotex Inc. | Apo-Quetiapine XR | 02457245 | 200 mg | M2214015 | 10/2025 |
Communications related to Quetiapine recalls:
- QUETIAPINE XR : Affected lots may exceed the established acceptable intake limit for N-nitroso-desalkyl-quetiapine (NNAP)
- APO-QUETIAPINE XR - May exceed the established acceptable intake limit for N-nitroso-desalkyl-quetiapine (NNAP). - Canada.ca
Quinapril recalls
| Company | Product name | DIN | Strength | Lot | Expiry |
|---|---|---|---|---|---|
| Pfizer Canada ULC | Accupril tablets | 01947672 | 10 mg | DY3042 | 03/2023 |
| Pfizer Canada ULC | Accupril tablets | 01947672 | 10 mg | CK5285 | 05/2022 |
| Pfizer Canada ULC | Accupril tablets | 01947680 | 20 mg | DT9592 | 03/2023 |
| Pfizer Canada ULC | Accupril tablets | 01947680 | 20 mg | CK6258 | 05/2022 |
| Pfizer Canada ULC | Accupril tablets | 01947680 | 20 mg | CK6259 | 05/2022 |
| Pfizer Canada ULC | Accupril tablets | 01947699 | 40 mg | DT9591 | 03/2023 |
| Pfizer Canada ULC | Accupril tablets | 01947699 | 40 mg | CM2828 | 05/2022 |
| Pfizer Canada ULC | Accupril tablets | 01947699 | 40 mg | CM2829 | 05/2022 |
| Pfizer Canada ULC | Accuretic tablets | 02237367 | 10/12.5 mg | FM9526 | 08/2023 |
| Pfizer Canada ULC | Accuretic tablets | 02237367 | 10/12.5 mg | FA3736 | 07/2022 |
| Pfizer Canada ULC | Accuretic tablets | 02237367 | 10/12.5 mg | EJ5192 | 07/2022 |
| Pfizer Canada ULC | Accuretic tablets | 02237368 | 20/12,5 mg | EX4411 | 07/2022 |
| Pfizer Canada ULC | Accuretic tablets | 02237368 | 20/12,5 mg | ET9511 | 07/2022 |
| Pfizer Canada ULC | Accuretic tablets | 02237368 | 20/12,5 mg | EF3087 | 07/2022 |
| Pfizer Canada ULC | Accuretic tablets | 02237369 | 20/25 mg | FA9224 | 07/2022 |
| Pfizer Canada ULC | Accuretic tablets | 02237369 | 20/25 mg | EA0781 | 07/2022 |
Communications related to quinapril recalls:
- Pfizer recalls Accupril and Accuretic tablets (April 21, 2022)
- Accupril Tabs: Nitrosamine impurity
- Accuretic (quinapril hydrochloride and hydrochlorothiazide): Nitrosamine Impurity
Ranitidine recalls
| Company | Product name | DIN | Strength | Lot | Date added |
|---|---|---|---|---|---|
| Pharmascience Inc. | ATOMA maximum strength acid reducer without prescription (24 tablets) | 02293471 | 150 mg | 629744F | 2022-03-11 |
| Pharmascience Inc. | ATOMA maximum strength acid reducer without prescription (24 tablets) | 02293471 | 150 mg | 632058H | 2022-03-11 |
| Pharmascience Inc. | Compliments maximum strength acid reducer without prescription (24 tablets) | 02293471 | 150 mg | 632043B | 2022-03-11 |
| Pharmascience Inc. | Compliments maximum strength acid reducer without prescription cool mint (24 tablets) | 02293471 | 150 mg | 629973A | 2022-03-11 |
| Pharmascience Inc. | CO-OP Care+ maximum strength acid reducer without prescription (24 tablets) | 02293471 | 150 mg | 629744C | 2022-03-11 |
| Pharmascience Inc. | Health One maximum strength acid reducer without prescription (32 tablets) | 02293471 | 150 mg | 629744J | 2022-03-11 |
| Pharmascience Inc. | Health One maximum strength acid reducer without prescription (32 tablets) | 02293471 | 150 mg | 632043H | 2022-03-11 |
| Pharmascience Inc. | Life Brand maximum strength acid reducer without prescription (24 tablets) | 02293471 | 150 mg | 629744H | 2022-03-11 |
| Pharmascience Inc. | Life Brand maximum strength acid reducer without prescription (24 tablets) | 02293471 | 150 mg | 632058I | 2022-03-11 |
| Pharmascience Inc. | Life Brand maximum strength acid reducer without prescription cool mint (48 tablets) | 02293471 | 150 mg | 629974B | 2022-03-11 |
| Pharmascience Inc. | Life Brand maximum strength acid reducer without prescription cool mint (24 tablets) | 02293471 | 150 mg | 629974A | 2022-03-11 |
| Pharmascience Inc. | Option+ maximum strength acid reducer without prescription (24 tablets) | 02293471 | 150 mg | 629744G | 2022-03-11 |
| Pharmascience Inc. | Option+ maximum strength acid reducer without prescription (24 tablets) | 02293471 | 150 mg | 632043D | 2022-03-11 |
| Pharmascience Inc. | Option+ maximum strength acid reducer without prescription (24 tablets) | 02293471 | 150 mg | 632043E | 2022-03-11 |
| Pharmascience Inc. | Option+ maximum strength acid reducer without prescription (8 tablets) | 02293471 | 150 mg | 632058A | 2022-03-11 |
| Pharmascience Inc. | Option+ maximum strength acid reducer without prescription cool mint (24 tablets) | 02293471 | 150 mg | 629973B | 2022-03-11 |
| Pharmascience Inc. | Option+ maximum strength acid reducer without prescription cool mint (24 tablets) | 02293471 | 150 mg | 631893C | 2022-03-11 |
| Pharmascience Inc. | PERSONNELLE maximum strength acid reducer without prescription (24 tablets) | 02293471 | 150 mg | 629744E | 2022-03-11 |
| Pharmascience Inc. | PERSONNELLE maximum strength acid reducer without prescription (24 tablets) | 02293471 | 150 mg | 632043A | 2022-03-11 |
| Pharmascience Inc. | PERSONNELLE maximum strength acid reducer without prescription (24 tablets) | 02293471 | 150 mg | 632043F | 2022-03-11 |
| Pharmascience Inc. | PERSONNELLE maximum strength acid reducer without prescription (24 tablets) | 02293471 | 150 mg | 632058J | 2022-03-11 |
| Pharmascience Inc. | PERSONNELLE maximum strength acid reducer without prescription (8 tablets) | 02293471 | 150 mg | 629744B | 2022-03-11 |
| Pharmascience Inc. | PERSONNELLE maximum strength acid reducer without prescription (8 tablets) | 02293471 | 150 mg | 632058B | 2022-03-11 |
| Pharmascience Inc. | PERSONNELLE maximum strength acid reducer without prescription cool mint (24 tablets) | 02293471 | 150 mg | 629973C | 2022-03-11 |
| Pharmascience Inc. | PERSONNELLE maximum strength acid reducer without prescription cool mint (48 tablets) | 02293471 | 150 mg | 629973D | 2022-03-11 |
| Pharmascience Inc. | PHARMASAVE maximum strength acid reducer without prescription (8 tablets) | 02293471 | 150 mg | 629744A | 2022-03-11 |
| Pharmascience Inc. | Rexall maximum strength acid reducer without prescription (24 tablets) | 02293471 | 150 mg | 629744I | 2022-03-11 |
| Pharmascience Inc. | Rexall maximum strength acid reducer without prescription (24 tablets) | 02293471 | 150 mg | 632043G | 2022-03-11 |
| Pharmascience Inc. | Rexall maximum strength acid reducer without prescription (24 tablets) | 02293471 | 150 mg | 632058G | 2022-03-11 |
| Pharmascience Inc. | Rexall maximum strength acid reducer without prescription (8 tablets) | 02293471 | 150 mg | 632058D | 2022-03-11 |
| Pharmascience Inc. | BIOMEDIC Acid Reducer (30 tablets) | 02247551 | 75 mg | 632952I | 2021-12-03 |
| Pharmascience Inc. | Life Brand Acid Reducer (30 tablets) | 02247551 | 75 mg | 632952K | 2021-12-03 |
| Pharmascience Inc. | OPTION+ Acid Reducer (10 tablets) | 02247551 | 75 mg | 632952B | 2021-12-03 |
| Pharmascience Inc. | OPTION+ Acid Reducer (40 tablets) | 02247551 | 75 mg | 633694B | 2021-12-03 |
| Pharmascience Inc. | Personnelle Acid Reducer (10 tablets) | 02247551 | 75 mg | 632952D | 2021-12-03 |
| Pharmascience Inc. | ATOMA maximum strength acid reducer without prescription (24 tablets) | 02293471 | 150 mg | 627765H | 2021-12-03 |
| Pharmascience Inc. | BIOMEDIC maximum strength acid reducer without prescription (24 tablets) | 02293471 | 150 mg | 627765I | 2021-12-03 |
| Pharmascience Inc. | BIOMEDIC maximum strength acid reducer without prescription (24 tablets) | 02293471 | 150 mg | 628471C | 2021-12-03 |
| Pharmascience Inc. | Compliments maximum strength acid reducer without prescription (24 tablets) | 02293471 | 150 mg | 628471D | 2021-12-03 |
| Pharmascience Inc. | CO-OP Care+ maximum strength acid reducer without prescription (24 tablets) | 02293471 | 150 mg | 627765D | 2021-12-03 |
| Pharmascience Inc. | Health One maximum strength acid reducer without prescription (32 tablets) | 02293471 | 150 mg | 628471A | 2021-12-03 |
| Pharmascience Inc. | London Drugs maximum strength acid reducer without prescription (24 tablets) | 02293471 | 150 mg | 627765E | 2021-12-03 |
| Pharmascience Inc. | Option+ maximum strength acid reducer without prescription (8 tablets) | 02293471 | 150 mg | 627765B | 2021-12-03 |
| Pharmascience Inc. | Option+ maximum strength acid reducer without prescription (24 tablets) | 02293471 | 150 mg | 627765G | 2021-12-03 |
| Pharmascience Inc. | PHARMASAVE maximum strength acid reducer without prescription (8 tablets) | 02293471 | 150 mg | 627765C | 2021-12-03 |
| Pharmascience Inc. | PHARMASAVE maximum strength acid reducer without prescription (24 tablets) | 02293471 | 150 mg | 628471B | 2021-12-03 |
| Pharmascience Inc. | Rexall maximum strength acid reducer without prescription (8 tablets) | 02293471 | 150 mg | 627765A | 2021-12-03 |
| Pharmascience Inc. | Rexall maximum strength acid reducer without prescription (24 tablets) | 02293471 | 150 mg | 627765F | 2021-12-03 |
| Pharmascience Inc. | Compliments Maximum Strength Acid Reducer (50 tablets) | 02293471 | 150mg | 628453 | 2021-02-05 |
| Pharmascience Inc. | CO-OP CARE + Maximum Strength Acid Reducer (24 tablets) | 02293471 | 150mg | 628308F | 2021-02-05 |
| Pharmascience Inc. | Life Brand Maximum Strength Acid Reducer (50 tablets) | 02293471 | 150mg | 628429 | 2021-02-05 |
| Pharmascience Inc. | Life Brand Maximum Strength Acid Reducer (24 tablets) | 02293471 | 150mg | 628308E | 2021-02-05 |
| Pharmascience Inc. | Option+ Maximum Strength Acid Reducer (8 tablets) | 02293471 | 150mg | 628308B | 2021-02-05 |
| Pharmascience Inc. | Personnelle Maximum Strength Acid Reducer (50 tablets) | 02293471 | 150mg | 628442 | 2021-02-05 |
| Pharmascience Inc. | PERSONNEL Maximum Strength Acid Reducer (8 tablets) | 02293471 | 150mg | 628308A 628308C |
2021-02-05 |
| Pharmascience Inc. | PERSONNEL Maximum Strength Acid Reducer (24 tablets) | 02293471 | 150mg | 628308D | 2021-02-05 |
| Pharmascience Inc. | pms-RANITIDINE | 02242453 | 150mg | 626718 623633 624871 626714 |
2021-02-05 |
| Pharmascience Inc. | ATOMA Acid Reducer (10 tablets) | 02247551 | 75 mg | 621791O | 2021-01-30 |
| Pharmascience Inc. | ATOMA Acid Reducer (30 tablets) | 02247551 | 75 mg | 621791X | 2021-01-30 |
| Pharmascience Inc. | BIOMEDIC Acid Reducer (30 tablets) | 02247551 | 75 mg | 621791K | 2021-01-30 |
| Pharmascience Inc. | BIOMEDIC Acid Reducer (30 tablets) | 02247551 | 75 mg | 621791U | 2021-01-30 |
| Pharmascience Inc. | Compliments Acid Reducer (60 tablets) | 02247551 | 75 mg | 621791D | 2021-01-30 |
| Pharmascience Inc. | Life Brand Acid Reducer (10 tablets) | 02247551 | 75 mg | 621791G | 2021-01-30 |
| Pharmascience Inc. | Life Brand Acid Reducer (10 tablets) | 02247551 | 75 mg | 621791P | 2021-01-30 |
| Pharmascience Inc. | Life Brand Acid Reducer (30 tablets) | 02247551 | 75 mg | 621791Q | 2021-01-30 |
| Pharmascience Inc. | Life Brand Acid Reducer (60 tablets) | 02247551 | 75 mg | 621791AA | 2021-01-30 |
| Pharmascience Inc. | London Drugs Acid Reducer (30 tablets) | 02247551 | 75 mg | 621791R | 2021-01-30 |
| Pharmascience Inc. | OPTION+ Acid Reducer (10 tablets) | 02247551 | 75 mg | 621791H | 2021-01-30 |
| Pharmascience Inc. | OPTION+ Acid Reducer (10 tablets) | 02247551 | 75 mg | 621791T | 2021-01-30 |
| Pharmascience Inc. | OPTION+ Acid Reducer (40 tablets) | 02247551 | 75 mg | 621791Y | 2021-01-30 |
| Pharmascience Inc. | Personnelle Acid Reducer (10 tablets) | 02247551 | 75 mg | 621791A | 2021-01-30 |
| Pharmascience Inc. | Personnelle Acid Reducer (10 tablets) | 02247551 | 75 mg | 621791N | 2021-01-30 |
| Pharmascience Inc. | Personnelle Acid Reducer (40 tablets) | 02247551 | 75 mg | 621791I | 2021-01-30 |
| Pharmascience Inc. | Personnelle Acid Reducer (40 tablets) | 02247551 | 75 mg | 621791Z | 2021-01-30 |
| Pharmascience Inc. | PHARMASAVE Acid Reducer (30 tablets) | 02247551 | 75 mg | 621791V | 2021-01-30 |
| Pharmascience Inc. | Rexall Acid Reducer (60 tablets) | 02247551 | 75 mg | 621791S | 2021-01-30 |
| Pharmascience Inc. | Rexall Acid Reducer (10 tablets) | 02247551 | 75 mg | 621791F | 2021-01-30 |
| Pharmascience Inc. | Rexall Acid Reducer (10 tablets) | 02247551 | 75 mg | 621791M | 2021-01-30 |
| Pharmascience Inc. | Rexall Acid Reducer (30 tablets) | 02247551 | 75 mg | 621791E | 2021-01-30 |
| Pharmascience Inc. | Rexall Acid Reducer (30 tablets) | 02247551 | 75 mg | 621791W | 2021-01-30 |
| Pharmascience Inc. | Acid Reducer (raniditine) sold under the brand name Compliments | 02247551 | 75 mg | 619254I | 2021-01-08 |
| Pharmascience Inc. | Acid Reducer (raniditine) sold under the brand name EXACT | 02247551 | 75 mg | 619254G | 2021-01-08 |
| Pharmascience Inc. | Acid Reducer (raniditine) sold under the brand name EXACT | 02247551 | 75 mg | 619254B | 2021-01-08 |
| Pharmascience Inc. | Acid Reducer (raniditine) sold under the brand name Life Brand | 02247551 | 75 mg | 624735C | 2021-01-08 |
| Pharmascience Inc. | Acid Reducer (raniditine) sold under the brand name Life Brand | 02247551 | 75 mg | 627539C | 2021-01-08 |
| Pharmascience Inc. | Acid Reducer (raniditine) sold under the brand name Life Brand | 02247551 | 75 mg | 619254H | 2021-01-08 |
| Pharmascience Inc. | Acid Reducer (raniditine) sold under the brand name Life Brand | 02247551 | 75 mg | 619254C | 2021-01-08 |
| Pharmascience Inc. | Acid Reducer (raniditine) sold under the brand name OPTION+ | 02247551 | 75 mg | 624735B | 2021-01-08 |
| Pharmascience Inc. | Acid Reducer (raniditine) sold under the brand name OPTION+ | 02247551 | 75 mg | 627539B | 2021-01-08 |
| Pharmascience Inc. | Acid Reducer (raniditine) sold under the brand name Personnelle | 02247551 | 75 mg | 624735A | 2021-01-08 |
| Pharmascience Inc. | Acid Reducer (raniditine) sold under the brand name Personnelle | 02247551 | 75 mg | 619254K | 2021-01-08 |
| Pharmascience Inc. | Acid Reducer (raniditine) sold under the brand name Personnelle | 02247551 | 75 mg | 627539A | 2021-01-08 |
| Pharmascience Inc. | Acid Reducer (raniditine) sold under the brand name PHARMASAVE | 02247551 | 75 mg | 619254J | 2021-01-08 |
| Pharmascience Inc. | PMS-Ranitidine 150 mg | 02242453 | 150 mg | 619003 | 2020-08-31 |
| Ranbaxy Pharmaceuticals Canada Inc. | Ran-Ranitidine | 02336480 | 150 mg | All lots | 2019-10-30 |
| Ranbaxy Pharmaceuticals Canada Inc. | Ran-Ranitidine | 02336502 | 300 mg | All lots | 2019-10-30 |
| Dominion Pharmacal | Maximum Strength Acid Reducer Without Prescription (ranitidine) sold under the brand name Personnelle | 02407523 | 150 mg | All lots | 2019-10-25 |
| Laboratoire Riva Inc. | Riva-Ranitidine 150 | 02247814 | 150 mg | All lots | 2019-10-25 |
| Laboratoire Riva Inc. | Riva-Ranitidine 300 | 02247815 | 300 mg | All lots | 2019-10-25 |
| Laboratoire Riva Inc. | Acid Reducer (ranitidine) sold under the brand names Biomedic, Circle K and Option+ | 02452464 | 75 mg | All lots | 2019-10-25 |
| Pharmascience Inc. | PMS-Ranitidine 150 mg | 02242453 | 150 mg | All lots | 2019-10-25 |
| Pharmascience Inc. | PMS-Ranitidine 300 mg | 02242454 | 300 mg | Al lots | 2019-10-25 |
| Pharmascience Inc. | Acid Reducer (ranitidine) sold under the brand names Atoma, Biomedic, Compliments, Exact, Life Brand, London Drugs, Option+, Personnelle, Pharmasave, Preferred Pharmacy, Rexall and Selection | 02247551 | 75 mg | All lots | 2019-10-25 |
| Pharmascience Inc. | Maximum Strength Acid Reducer Without Prescription (ranitidine) sold under the brand names Atoma, Biomedic, Compliments, Co-op Care+, Equate, Exact, Health One, Kirkland Signature, London Drugs, Option+, Personnelle, Pharmasave, Rexall and Selection | 02293471 | 150 mg | All lots | 2019-10-25 |
| Pharmascience Inc. | Acid Reducer (ranitidine) sold under the brand names Exact and Life Brand | 02400103 | 150 mg | All lots | 2019-10-25 |
| Vita Health Products Inc. | Acid Reducer (ranitidine) sold under the brand names Equate, iPharma, Stanley and Western Family | 02298740 | 75 mg | All lots | 2019-10-25 |
| Vita Health Products Inc. | Maximum Strength Acid Reducer (ranitidine) sold under the brand names Equate, iPharma and Western Family | 02298902 | 150 mg | All lots | 2019-10-25 |
| Sanofi Consumer Health Inc. | Zantac (ranitidine) | 02230287 | 75 mg | All lots | 2019-10-18 |
| Sanofi Consumer Health Inc. | Zantac Maximum Strength Non-Prescription (ranitidine) | 02277301 | 150 mg | All lots | 2019-10-18 |
| Sivem Pharmaceuticals ULC | Ranitidine | 02385953 | 150 mg | K46484 K46485 K48440 K48679 K50204 K50206 K50207 K50590 K50594 K50677 K50908 K50925 K50928 K50932 K50935 K51080 |
2019-10-18 |
| Sivem Pharmaceuticals ULC | Ranitidine | 02385961 | 300 mg | K50624 K50941 K50947 K50950 |
2019-10-18 |
| Teva Canada Limited | Act Ranitidine | 02248570 | 150 mg | All lots | 2019-10-18 |
| Teva Canada Limited | Act Ranitidine | 02248571 | 300 mg | All lots | 2019-10-18 |
| Apotex Inc. | Acid Reducer (ranitidine) sold under the brand names Equate and Selection | 02296160 | 150 mg | All lots | 2019-09-25 |
| Apotex Inc. | Apo-Ranitidine Oral Solution | 02280833 | 15 mg/mL | All lots | 2019-09-25 |
| Apotex Inc. | Apo-Ranitidine Tablet 150 mg | 00733059 | 150 mg | All lots | 2019-09-25 |
| Apotex Inc. | Apo-Ranitidine Tablet 300 mg | 00733067 | 300 mg | All lots | 2019-09-25 |
| Pro Doc Limitée | Ranitidine - 150 mg | 00740748 | 150 mg | All lots | 2019-09-25 |
| Pro Doc Limitée | Ranitidine - 300 mg | 00740756 | 300 mg | All lots | 2019-09-25 |
| Sanis Health Inc. | Ranitidine | 02353016 | 150 mg | All lots | 2019-09-25 |
| Sanis Health Inc. | Ranitidine | 02353024 | 300 mg | All lots | 2019-09-25 |
| Sivem Pharmaceuticals ULC | Ranitidine | 02385953 | 150 mg | NP4179 NP4183 NP4184 NP5656 NP5657 NT2721 NT2722 NT2724 NT2757 NT2762 NT2763 NT2764 NT2765 PJ2434 PJ2435 PV6243 PV6244 PV6245 |
2019-09-25 |
| Sivem Pharmaceuticals ULC | Ranitidine | 02385961 | 300 mg | NP4177 NP4180 NT1365 PX8854 |
2019-09-25 |
| Sandoz Canada | Sandoz Ranitidine | 02243229 | 150 mg | All lots | 2019-09-17 |
| Sandoz Canada | Sandoz Ranitidine | 02243230 | 300 mg | All lots | 2019-09-17 |
Communications related to ranitidine recalls:
Sitagliptin recalls
| Company | Product Name | DIN | Strength | Lot | Expiry |
|---|---|---|---|---|---|
| Accord Healthcare Inc. | ACH-Sitagliptin | 02512475 | 25 mg | P2206573 | 10/2024 |
| Accord Healthcare Inc. | ACH-Sitagliptin | 02512483 | 50 mg | P2206574 | 10/2024 |
| Accord Healthcare Inc. | ACH-Sitagliptin | 02512491 | 100 mg | P2206575 | 10/2024 |
| Accord Healthcare Inc. | ACH-Sitagliptin | 02512491 | 100 mg | P2206981 | 10/2024 |
Communications related to Sitagliptin recalls:
Varenicline recalls
Recall is still outstanding for a single lot from Pfizer, please refer to the Dear Health Care Professional letter for more details.
| Company | Product name | DIN | Strength | Lot | Expiry |
|---|---|---|---|---|---|
| Teva Canada Ltd. | TEVA-VARENICLINE TABLETS | 02426226 | 0.5mg | K60795 | 31/10/2021 |
| Teva Canada Ltd. | TEVA-VARENICLINE TABLETS | 02426234 | 1mg | K60783 | 30/4/2021 |
| Teva Canada Ltd. | TEVA-VARENICLINE TABLETS | 02426234 | 1mg | K60784 | 30/4/2021 |
| Teva Canada Ltd. | TEVA-VARENICLINE COMBO TABLETS | 02426781 | 0.5mg/ 1mg | K60796 | 30/4/2021 |
| Pfizer Canada ULC | CHAMPIX Tablet, Kit | 02298309 | 0.5mg and 1mg | 00019062 | 08/2021 |
| Pfizer Canada ULC | CHAMPIX Tablet, Kit | 02298309 | 0.5mg and 1mg | 00020452 | 12/2021 |
| Pfizer Canada ULC | CHAMPIX Tablet, Kit | 02298309 | 0.5mg and 1mg | 00020451 | 01/2022 |
| Pfizer Canada ULC | CHAMPIX Tablet | 02291177 | 0.5mg | ED7397 | 05/2022 |
Communications related to varenicline recalls:
Page details
- Date modified: